| pS6 < 4 (n = 22) | pS6 ≥ 4 (n = 17) | P value |
Age (y) | 74.1 ± 7.4 | 73.5 ± 5.2 | 0.792 |
Sex (male/female) | 18/4 | 13/4 | 0.683 |
Body mass index (kg/m2) | 22.3 ± 3.1 | 22.2 ± 3.9 | 0.882 |
CEA (ng/mL) | 3.3 ± 1.9 | 4.7 ± 3.7 | 0.144 |
CA19-9 (U/mL) | 23.4 ± 21.7 | 1481.5 ± 3335.3 | 0.047* |
SUV max of FDG-PET | 4.8 ± 0.7 | 11.2 ± 6.4 | 0.002* |
Tumor size (mm) | 34.1 ± 17.0 | 38.1 ± 15.8 | 0.456 |
Tumor type (Papillary/Nodular/Flat) | 2/13/7 | 0/12/5 | 0.080 |
T Stage (≤ 2/3 ≤) | 16/6 | 4/13 | 0.002* |
Nodal status (N0/N1/N2) | 16/4/2 | 9/7/1 | 0.285 |
Lymphatic invasion (-/ +) | 13/9 | 5/12 | 0.063 |
Vascular invasion (-/ +) | 13/9 | 5/12 | 0.063 |
Nerve invasion (-/ +) | 6/16 | 3/14 | 0.475 |
UICC Stage (≤ IIA/IIB ≤) | 13/9 | 2/15 | 0.003* |
 | GLUT-1 < 4 (n = 22) | GLUT-1 ≥ 4 (n = 17) | P value |
Age (y) | 73.9 ± 7.3 | 73.7 ± 5.3 | 0.946 |
Sex (male/female) | 18/4 | 13/4 | 0.683 |
Body mass index (kg/m2) | 22.1 ± 3.1 | 22.4 ± 3.8 | 0.748 |
CEA (ng/mL) | 3.3 ± 1.9 | 4.7 ± 3.7 | 0.118 |
CA19-9 (U/mL) | 24.3 ± 21.8 | 1480.4 ± 3335.8 | 0.047* |
SUV max of FDG-PET | 4.8 ± 1.3 | 10.6 ± 1.4 | 0.007* |
Tumor size (mm) | 35.5 ± 19.3 | 36.2 ± 4.0 | 0.899 |
Tumor type (Papillary/Nodular/Flat) | 2/12/8 | 0/13/4 | 0.379 |
T Stage (≤ 2/3 ≤) | 15/7 | 5/12 | 0.025* |
Nodal status (N0/N1/N2) | 18/2/2 | 7/9/1 | 0.009* |
Lymphatic invasion (-/ +) | 14/8 | 4/13 | 0.023* |
Vascular invasion (-/ +) | 13/9 | 5/12 | 0.063 |
Nerve invasion (-/ +) | 7/15 | 2/15 | 0.251 |
UICC Stage (≤ IIA/IIB ≤) | 13/9 | 2/15 | 0.003* |